Vanda Pharmaceuticals Inc. · NASDAQ:VNDA

Vanda Pharmaceuticals — Technical Presentation (May 2009)

5 slides from Vanda Pharmaceuticals's technical presentation, May 18, 2009

  1. Slide 1: Similar Molecular Signature of Antipsychotics and Selective Estrogen Receptor Modulators

    Table 1. Similar Molecular Signature of Antipsychotics and Selective Estrogen Receptor Modulators‡ Figure 4. Effect of Antipsychotics on the Biosynthesis of Fatty Acids and Cholesterol Figure 3. Expression Changes by Selective Estrogen Receptor Modulators of Top Ranked Probe Sets of the Antipsychoti

  2. Slide 2: Comparison of Dropout Rates in Active Treatment Arms of PCTs and ACTs

    Table 2. Comparison of Dropout Rates in Active Treatment Arms of PCTs and ACTs Figure 3. PANSS Total Score: Mean Change from Baseline at Week 6, LOCF Analysis of Studies 3000, 3001, 3002, and 3003 Figure 2. Reasons for Discontinuation: A. Active Treatment Arms in PCT and ACTs and B. Placebo Arm and

  3. Slide 3: Genotype Effect of DRD2 SNPs on Iloperidone Efficacy

    Figure 3. Genotype Effect of DRD2 SNPs on Iloperidone Efficacy at Day 14 Figure 2. Baseline PANSS-T Score and DRD2 Genotypes Figure 4. Taq1A Genotype Effect on Iloperidone Response Table 1. DRD2 Polymorphisms Analyzed Table 2. Allele and Genotype Frequencies Figure 1. Genome View of the DRD2 Gene an

  4. Slide 4: Mean Change from Baseline, BPRS by Drop-out Cohorts

    Figure 4. 95% Confidence Intervals Figure 1. Mean Change from Baseline, BPRS by Drop-out Cohorts Figure 2. Patients Treated ^ 14 Days - BPRS Figure 3. Patients Treated ^ 14 Days - PANSS-T Table 2. Adjusted Mean Change on BPRS and PANSS-T Table 1. Randomization and Titration Schedules A b s t r a c t

  5. Slide 5: Genotype Effect in the 6-month Extension Period for Iloperidone Patients

    Figure 5. Genotype Effect in the 6-month Extension Period for Patients Previously Treated with a Placebo or Ziprasidone Figure 4. Genotype Effect in the Extension Phase (Day 29 to 203) for Patients Previously Treated with Placebo or Ziprasidone (Day 0 to 28) Figure 3. Study Design Figure 1. Efficacy

Vanda Pharmaceuticals — Technical Presentation (May 2009) on 6ix